These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22581095)

  • 1. Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI).
    Yokogawa N; Tanikawa A; Amagai M; Kato Y; Momose Y; Arai S; Eto H; Ikeda T; Furukawa F
    Mod Rheumatol; 2013 Mar; 23(2):318-22. PubMed ID: 22581095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI).
    Yokogawa N; Kato Y; Sugii S; Inada S
    Mod Rheumatol; 2012 Apr; 22(2):249-55. PubMed ID: 21842436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study.
    Ikeda T; Kanazawa N; Furukawa F
    J Dermatol; 2012 Jun; 39(6):531-5. PubMed ID: 22168306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus.
    Momose Y; Arai S; Eto H; Kishimoto M; Okada M
    J Dermatol; 2013 Feb; 40(2):94-7. PubMed ID: 23216212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
    Wakiya R; Kameda T; Nakashima S; Shimada H; Fahmy Mansour MM; Kato M; Miyagi T; Kadowaki N; Dobashi H
    Intern Med; 2020 Sep; 59(17):2105-2112. PubMed ID: 32522920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus.
    Wakiya R; Kameda T; Ueeda K; Nakashima S; Shimada H; Mansour MF; Kato M; Miyagi T; Miyatake N; Kadowaki N; Dobashi H
    Lupus; 2019 Jun; 28(7):826-833. PubMed ID: 31068068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial.
    Yokogawa N; Eto H; Tanikawa A; Ikeda T; Yamamoto K; Takahashi T; Mizukami H; Sato T; Yokota N; Furukawa F
    Arthritis Rheumatol; 2017 Apr; 69(4):791-799. PubMed ID: 27992698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
    Morita S; Takahashi T; Yoshida Y; Yokota N
    Ther Drug Monit; 2016 Apr; 38(2):259-67. PubMed ID: 26587870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of cutaneous disease activity in early lupus and its correlation with quality of life: a cross-sectional study.
    Hinduja N; Mv P; Padhee S; Maikap D; Padhan P; Kar HK; Misra R; Srinivas CR; Ahmed S
    Rheumatol Int; 2023 Oct; 43(10):1835-1840. PubMed ID: 37310437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
    Hosokawa Y; Oiwa H
    Intern Med; 2020 Oct; 59(20):2485-2490. PubMed ID: 32641656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous Toll-like Receptor 9 Pre-Defines Hydroxychloroquine Dosage in Patients with Both Discoid and Subacute Lupus Erythematosus.
    Englert KA; Dyduch G; Kłosowicz A; Spałkowska M; Jaworek AK; Migacz-Gruszka K; Jarosz-Chudek A; Mercuri SR; Szpor J; Mazzoccoli G; Damiani G; Wojas-Pelc A
    Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38004071
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of hydroxychloroquine for treating annular erythema associated with Sjögren's syndrome.
    Arakawa H; Tanese K; Tanaka R; Murakami K; Sujino K; Miyamoto J; Amagai M; Tanikawa A
    J Dermatol; 2021 Oct; 48(10):1526-1532. PubMed ID: 34254339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history of disease activity and damage in patients with cutaneous lupus erythematosus.
    Ker KJ; Teske NM; Feng R; Chong BF; Werth VP
    J Am Acad Dermatol; 2018 Dec; 79(6):1053-1060.e3. PubMed ID: 29969701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures.
    Jolly M; Kazmi N; Mikolaitis RA; Sequeira W; Block JA
    J Am Acad Dermatol; 2013 Apr; 68(4):618-623. PubMed ID: 23107310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus.
    Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
    Intern Med; 2019 May; 58(9):1257-1262. PubMed ID: 30626831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The study of Cutaneous Lupus Erythematosus Disease Area and Severity Index in Indian patients with systemic lupus erythematosus.
    Salphale P; Danda D; Chandrashekar L; Peter D; Jayaseeli N; George R
    Lupus; 2011 Dec; 20(14):1510-7. PubMed ID: 21997966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus.
    Bonilla-Martinez ZL; Albrecht J; Troxel AB; Taylor L; Okawa J; Dulay S; Werth VP
    Arch Dermatol; 2008 Feb; 144(2):173-80. PubMed ID: 18283174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous lupus erythematosus: factors related to cutaneous activity and damage in a cohort of 260 patients from A Coruña, Spain.
    Arévalo-Bermúdez MDP; Paradela S; Balboa-Barreiro V; Fonseca E
    Lupus; 2020 Aug; 29(9):1021-1030. PubMed ID: 32539659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.